Insider purchase: Opus Genetics director increases stake to 254,818 shares
Rhea-AI Filing Summary
Opus Genetics, Inc. director Sean Ainsworth reported an open-market purchase of 86,956 shares of the company's common stock on 08/25/2025 at a price of $1.15 per share, increasing his beneficial ownership to 254,818 shares. The Form 4 was signed via power of attorney on 08/27/2025. The filing shows no reported derivative transactions.
Positive
- Director purchase reported: Sean Ainsworth acquired 86,956 common shares, increasing his stake to 254,818 shares.
- Transparent disclosure: The transaction was reported on Form 4 and signed by power of attorney on 08/27/2025.
Negative
- None.
Insights
TL;DR: A director increased direct ownership by 86,956 shares at $1.15, modest insider purchase that raises alignment with shareholders.
The reported transaction is a straightforward non-derivative acquisition: 86,956 common shares were purchased on 08/25/2025 for $1.15 each, bringing the reporting person’s total to 254,818 shares. The Form 4 contains no derivative positions or dispositions. The filing was executed by power of attorney and properly reported within a standard timeframe.
TL;DR: Director purchase disclosed timely; strengthens insider alignment but provides limited material insight alone.
The disclosure documents an insider purchase by a director, which generally signals increased alignment between management and shareholders. The form does not disclose any option exercises or derivative activity. No amendments or additional reporting persons are indicated. As a single Form 4 with a routine purchase, it appears to be a standard Section 16 disclosure without other governance events.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 86,956 | $1.15 | $100K |
Footnotes (1)
